Loading
Latest filing published 13 Jun 2024 for NexImmune, Inc., €0.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
No signal scores available.
Kristi Jones is a declared insider at 2 companies (chief executive); the most frequent names are NexImmune, Inc. and NexImmune, Inc. Over a trading history stretching from 17 February 2021 to 11 June 2024, the count stands at 5 filings.
Purchases make up the whole of the open-market record (3 purchases, €47k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant. 2024 to date brings 1 purchase and no sales.
The median purchase comes to €13k.
On 13 June 2024 came the latest disclosure, an open-market purchase for €0 in NexImmune, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations